We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Reagent Red Cell Products Unveiled at Annual Blood Banking Meeting

By LabMedica International staff writers
Posted on 03 Nov 2014
Four new reagent red cell diagnostic products were unveiled at a blood banking meeting.

The annual meeting of the American Association of Blood Banks (AABB) that was held in Philadelphia, PA, USA from October 25–28, 2014, was selected for the launch of new red cell reagent diagnostic products produced by Quotient Limited (St Helier, Jersey).

The four new products are: (1) ALBAcyte Expanded Rh Negative Antibody Screen, (2) ALBAcyte Antibody Identification Panel (16-cell), (3) ALBAcyte Antibody Screen (two-cell), and (4) ALBAzyme Papain Solution Kit.

The ALBAcyte Expanded Rh Negative Antibody Screen will be of particular use with pregnant, Rh-negative women who have been treated with Rh immunoglobulin. More...
Its Rh-negative cells detect all the unexpected antibodies required of traditional screens. The ALBAcyte Antibody Identification Panel (16-cell) is a full antibody identification panel with six complementary cells. The ALBAcyte Antibody Screen (two-cell) is a robust antibody screen for those laboratories that prefer a two-cell screen, or frequently test pediatric or other small-volume samples. Red cells incorporated in this product have been carefully selected to maximize homozygosity, thus optimizing the detection of antibodies. The ALBAzyme Papain Solution Kit is a kit combining both papain and enzyme control, which pairs with the existing papain-treated ALBAcyte Antibody Identification Panel (10-cell), to better allow laboratories to treat and test auto-controls and patient samples.

"These four new products expand our reagent red cell offering, including the addition of a number of novel products," said Jeremy Stackawitz, president of Quotient Limited. "Quotient's product offering can now address all the needs of the vast majority of blood bank laboratories, truly making it a one-stop-shop for reagent red cells."

Related Links:
Quotient Limited



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Pipette Calibration System
Artel PCS®
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.